# GEMDOCE (NCT04386746)

> Intravesical Gemcitabine and Docetaxel for BCG naïve Non-muscle Invasive Bladder Cancer

No report yet. It can be ordered.

- Drugs tested: gemcitabine plus docetaxel
- Indication: BCG-naïve non-muscle invasive urothelial carcinoma of the bladder

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04386746
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Conditions: Urothelial Carcinoma Bladder; Bladder Cancer
- Interventions: Gemcitabine; Docetaxel
- Enrollment: 27
- Primary outcome: 3-Month Complete Response Rate

## Indexed commentary on GEMDOCE so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=gemdoce-nct04386746